Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference

Bibliography

• RAVDIN PM, CRONIN KA, HOWLANDER N et al.: A sharp decrease in breast cancer incidence in the United States in 2003. Breast Cancer Res. Treat. (2006) 100:S6 Abstr. 5.
   Google Scholar
• ROSSOUW JE, ANDERSON GL, PRENTICE RL et al.: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 288:321-333.
   PubMed Web of Science ®Google Scholar
• BERAL V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 362:419-427.
   PubMed Web of Science ®Google Scholar
• CUZICK J, FORBES J, EDWARDS R et al.: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 360:817-824.
   PubMed Web of Science ®Google Scholar
• CUZICK J: Long term efficacy of tamoxifen for chemoprevention-results of the IBIS-I study. Breast Cancer Res. Treat. (2006) 100:S16 Abstr. 34.
   Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. (1998) 90:1371-1388.
   Google Scholar
• FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. (2005) 97:1652-1662.
   Google Scholar
• CHLEBOWSKI RT, BLACKBURN GL, THOMSON CA et al.: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl. Cancer Inst. (2006) 98:1767-1776.
   Google Scholar
• CHLEBOWSKI RT, BLACKBURN GL, ELASHOFF RM et al.: Mature analysis from the women's intervention nutrition study (WINS) evaluationg dietary fat reduction and breast cancer outcome. Breast Cancer Res. Treat. (2006) 100:32 Abstr. S16.
   Google Scholar
• MONTEMURRO F, VALABREGA G, AGLIETTA M: Trastuzumab-based combination therapy for breast cancer. Expert Opin. Pharmacother. (2004) 5:81-96.
   Google Scholar
• OSBORNE CK, SHOU J, MASSARWEH S et al.: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin. Cancer Res. (2005) 11:865s-870s.
   Google Scholar
• JOHNSTON SR: Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin. Cancer Res. (2005) 11:889s-899s.
   Google Scholar
• MACKEY JR, KAUFMAN B, CLEMENS M et al.: Trastuzumab prolongs progression-free survival in in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res. Treat. (2006) 100:S5 Abstr. 3.
   Google Scholar
• PEGRAM M, CHAN D, DICHMANN RA et al.: Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. Breast Cancer Res. Treat. (2006) 100:S28 Abstr. 301.
   Google Scholar
• KONECNY GE, MENG YG, UNTCH M et al.: Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res. (2004) 10:1706-1716.
   Google Scholar
• MONTEMURRO F, VALABREGA G, AGLIETTA M: Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert. Opin. Biol. Ther. (2007) 7:257-268.
   Google Scholar
• GEYER CE, FORSTER J, LINDQUIST D et al.: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J Med. (2006) 355:2733-2743.
   PubMed Web of Science ®Google Scholar
• CAMERON D, STEIN S, ZAKS T et al.: Lapatinib plus capecitabine shows superior efficacy compared to capecitabine alone in patients with ErbB2 positive advanced or metastatic breast cancer - initial biomarker data. Breast Cancer Res. Treat. (2006) 100:S5 Abstr. 2.
   Google Scholar
• CRISTOFANILLI M, BOUSSEN H, BASELGA J et al.: A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC). Breast Cancer Res. Treat. (2006) 100:S5 Abstr. 1.
   Google Scholar
• GOMEZ HL, CHAVEZ MA, DOVAL DG et al.: Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer. Breast Cancer Res. Treat. (2006) 100:S68 Abstr. 1090.
   Google Scholar
• EBCTCG SECRETARIAT: Highlights from the early breast cancer trialists' collaborative group (EBCTCG) 2005 – 2006 worldwide overview. Breast Cancer Res. Treat. (2006) 100:S19 Abstr. 40.
   Google Scholar
• BAEHNER FL, HABEL LA, QUESENBERRY CP et al.: Quantitative RT-PCR analysis of ER and PR by oncotype DX indicates distinct and different associations with prognosis and prediction of tamoxifen benefit. Breast Cancer Res. Treat. (2006) 100:S20 Abstr. 45.
   Google Scholar
• KOK M, LINN SC, WESSELS LF et al.: Robust cross-platform validation of 81-gene tamoxifen resistance signature, the Amsterdam/Rotterdam collaboration (TAMRO). Breast Cancer Res. Treat. (2006) 100:S21 Abstr. 47.
   Google Scholar
• MOEBUS VJ, LUECK HJ, THOMSSEN C et al.: Dose-dense sequential chemotherapy with epirubicin (E), paclitaxel (T) and cyclophosphamide (C) (ETC) in comparison with conventional schedule chemotherapy in high-risk breast cancer patients (>=4+ LN). Mature results of an AGO-trial. Breast Cancer Res. Treat. (2006) 100:S20 Abstr. 43.
   Google Scholar
• BURNELL M, LEVINE M, CHAPMAN JA et al.: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: results of an interim analysis. Presented at the 29th San Antonio Breast Cancer Symposium. San Antonio, TX, USA (14 – 17 December 2006) Abstr. 53.
   Google Scholar
• LEVINE MN, PRITCHARD KI, BRAMWELL VH et al.: Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J. Clin. Oncol. (2005) 23:5166-5170.
   Google Scholar
• HENDERSON IC, BERRY DA, DEMETRI GD et al.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J. Clin. Oncol. (2003) 21:976-983.
   Google Scholar
• PRITCHARD KI, SHEPHERD LE, O'MALLEY FP et al.: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. (2006) 354:2103-2111.
   PubMed Web of Science ®Google Scholar
• GENNARI A, SORMANI MP, PUNTONI M et al.: A pooled analysis on the interaction between HER-2 expression and responsiveness of breast cancer to adjuvant chemotherapy. Breast Cancer Res. Treat. (2006) 100:S19 Abstr. 41.
   Google Scholar
• SLAMON D, EIERMANN W, ROBERT N et al.: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res. Treat. (2005) 94:S5 Abstr. 1.
   Google Scholar
• GHERSI D, WILCKEN N, SIMES RJ: A systematic review of taxane-containing regimens for metastatic breast cancer. Br. J. Cancer (2005) 93:293-301.
   PubMed Web of Science ®Google Scholar
• JONES SE, ERBAN J, OVERMOYER B et al.: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. (2005) 23:5542-5551.
   Google Scholar
• GRADISHAR W, KRASNOJON D, CHEPOROV S et al.: A randomized phase II trial of qw or q3w ABI-007 (ABX) vs. q3W solvent-based docetaxel (TXT) as first-line therapy in metastatic breast cancer (MBC). Breast Cancer Res. Treat. (2006) 100:S21 Abstr. 46.
   Google Scholar
• SCHWARTZBERG LS, ARENA F, MINTZER D et al.: Phase II trial of nanoparticle albumin-bound paclitaxel (ABX) + capecitabine (XEL) in first line treatment of metastatic breast cancer (MBC): interim results. Breast Cancer Res. Treat. (2006) 100:S70 Abstr. 1096.
   Google Scholar
• ROBIDOUX A, BUYSE M, BUZDAR A et al.: Neoadjuvant chemotherapy with sequential weekly nanoparticle albumin-bound paclitaxel (ABI-007, Abraxane) followed by 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in locally advanced breast cancer (LABC): a phase II trial of the NSABP Foundation research programs (FRP). Breast Cancer Res. Treat. (2006) 100:S147 Abstr. 3068.
   Google Scholar
• LINK JS, WAISMAN JR, JACOBS CI: Bevacizumab (avastin) and albumin bound paclitaxel (abraxane) treatment in metastatic breast cancer. Breast Cancer Res. Treat. (2006) 100:S69 Abstr. 1095.
   Google Scholar
• WINER EP, HUDIS C, BURSTEIN HJ et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. (2005) 23:619-629.
   Google Scholar
• CUZICK J, WALE C, ON BEHALF OF THE ATAC TRIALISTS' GROUP: A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years' treatment. Breast Cancer Res. Treat. (2006) 100:S24 Abstr. 104.
   Google Scholar
• BRUFSKY A, BUNDRED N, COLEMAN R et al.: An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res. Treat. (2006) 100:S25 Abstr. 107.
   Google Scholar
• DOWSETT M, CUZICK J, WALE C et al.: Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J. Clin. Oncol. (2005) 23:7512-7517.
   Google Scholar
• DOWSETT M, ALLRED DC: Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res. Treat. (2006) 100:S21 Abstr. 48.
   Google Scholar
• GRADISHAR WJ, CHIA S, PICCART-GEBHART MJ: Fulvestrant versus examestane following prior non-steroidal aromatase inhibitor therapy: first results from EFECT, a randomized, phase III trial in post menopausal women with advanced breast cancer. Breast Cancer Res. Treat. (2006) 100:S8 Abstr. 12.
   Google Scholar